Login Register Cart 0
Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Stem Cells Treatment for Wilson Disease

Author(s): Shan Tang, Li Bai, Zhongping Duan and Sujun Zheng*

Volume 17, Issue 8, 2022

Published on: 24 November, 2021

Page: [712 - 719] Pages: 8

DOI: 10.2174/1574888X16666211006111556

Price: $65

Abstract

Wilson Disease (WD) is a copper excretion disorder, mainly caused by mutations in the ATP7B gene. Pharmacological therapies and liver transplantation are currently the main treatment methods for WD, but they face problems such as drug treatment compliance, adverse reactions, and shortage of liver donors. Stem cell therapy of WD may correct abnormal copper metabolism permanently, which is the focus of current research. In this review, we summarized the latest research on stem cells treatment for WD, as well as current challenges and future expectations.

Keywords: Stem cells, liver disease, stem cell-based therapy, wilson disease, treatment, regeneration.

« Previous Next »
[1]
Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol 2015; 14(1): 103-13.
[http://dx.doi.org/10.1016/S1474-4422(14)70190-5] [PMID: 25496901]
[2]
Schilsky ML. Wilson Disease: Diagnosis, Treatment, and Follow-up. Clin Liver Dis 2017; 21(4): 755-67.
[http://dx.doi.org/10.1016/j.cld.2017.06.011] [PMID: 28987261]
[3]
Litwin T, Dzieżyc K, Członkowska A. Wilson disease-treatment perspectives. Ann Transl Med 2019; 7(Suppl. 2): S68.
[http://dx.doi.org/10.21037/atm.2018.12.09] [PMID: 31179305]
[4]
Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson’s disease in the United Kingdom. Brain 2013; 136(Pt 5): 1476-87.
[http://dx.doi.org/10.1093/brain/awt035] [PMID: 23518715]
[5]
Mulligan C, Bronstein JM. Wilson disease: an overview and approach to management. Neurol Clin 2020; 38(2): 417-32.
[http://dx.doi.org/10.1016/j.ncl.2020.01.005] [PMID: 32279718]
[6]
Nagral A, Sarma MS, Matthai J, et al. Wilson’s disease: clinical practice guidelines of the indian national association for study of the liver, the indian society of pediatric gastroenterology, hepatology and nutrition, and the movement disorders society of india. J Clin Exp Hepatol 2019; 9(1): 74-98.
[http://dx.doi.org/10.1016/j.jceh.2018.08.009] [PMID: 30765941]
[7]
Roberts EA. Update on the diagnosis and management of wilson disease. Curr Gastroenterol Rep 2018; 20(12): 56.
[http://dx.doi.org/10.1007/s11894-018-0660-7] [PMID: 30397835]
[8]
EASL clinical practice guidelines: wilson's disease. J Hepatol 2012; 56(3): 671-85.
[PMID: 22340672]
[9]
Zimbrean PC, Schilsky ML. The spectrum of psychiatric symptoms in Wilson’s disease: treatment and prognostic considerations. Am J Psychiatry 2015; 172(11): 1068-72.
[http://dx.doi.org/10.1176/appi.ajp.2015.15030371] [PMID: 26575449]
[10]
Litwin T, Dušek P, Członkowska A. Symptomatic treatment of neurologic symptoms in wilson disease. Handb Clin Neurol 2017; 142: 211-23.
[http://dx.doi.org/10.1016/B978-0-444-63625-6.00018-5] [PMID: 28433105]
[11]
Masełbas W, Członkowska A, Litwin T, Niewada M. Persistence with treatment for Wilson disease: a retrospective study. BMC Neurol 2019; 19(1): 278.
[http://dx.doi.org/10.1186/s12883-019-1502-4] [PMID: 31718567]
[12]
Schilsky ML. Liver transplantation for Wilson’s disease. Ann N Y Acad Sci 2014; 1315: 45-9.
[http://dx.doi.org/10.1111/nyas.12454] [PMID: 24820352]
[13]
Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47(6): 2089-111.
[http://dx.doi.org/10.1002/hep.22261] [PMID: 18506894]
[14]
Weiss KH, Schäfer M, Gotthardt DN, et al. Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. Clin Transplant 2013; 27(6): 914-22.
[http://dx.doi.org/10.1111/ctr.12259] [PMID: 24118554]
[15]
Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl 2005; 11(4): 441-8.
[http://dx.doi.org/10.1002/lt.20352] [PMID: 15776453]
[16]
Jaber FL, Sharma Y, Gupta S. Demonstrating potential of cell therapy for wilson’s disease with the long-evans cinnamon rat model. Methods Mol Biol 2017; 1506: 161-78.
[http://dx.doi.org/10.1007/978-1-4939-6506-9_11] [PMID: 27830552]
[17]
Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: From liver transplantation to cell factory. J Hepatol 2015; 62(1)(Suppl.): S157-69.
[http://dx.doi.org/10.1016/j.jhep.2015.02.040] [PMID: 25920085]
[18]
Filippi C, Dhawan A. Current status of human hepatocyte transplantation and its potential for Wilson’s disease. Ann N Y Acad Sci 2014; 1315: 50-5.
[http://dx.doi.org/10.1111/nyas.12386] [PMID: 24605914]
[19]
Trounson A, McDonald C. Stem Cell Therapies in Clinical Trials: Progress and Challenges. Cell Stem Cell 2015; 17(1): 11-22.
[http://dx.doi.org/10.1016/j.stem.2015.06.007] [PMID: 26140604]
[20]
Kopp JL, Grompe M, Sander M. Stem cells versus plasticity in liver and pancreas regeneration. Nat Cell Biol 2016; 18(3): 238-45.
[http://dx.doi.org/10.1038/ncb3309] [PMID: 26911907]
[21]
Wang J, Sun M, Liu W, Li Y, Li M. Stem cell-based therapies for liver diseases: an overview and update. Tissue Eng Regen Med 2019; 16(2): 107-18.
[http://dx.doi.org/10.1007/s13770-019-00178-y] [PMID: 30989038]
[22]
Itoh T, Miyajima A. Liver regeneration by stem/progenitor cells. Hepatology 2014; 59(4): 1617-26.
[http://dx.doi.org/10.1002/hep.26753] [PMID: 24115180]
[23]
Lorincz MT. Wilson disease and related copper disorders. Handb Clin Neurol 2018; 147: 279-92.
[http://dx.doi.org/10.1016/B978-0-444-63233-3.00018-X] [PMID: 29325617]
[24]
Gerosa C, Fanni D, Congiu T, et al. Liver pathology in Wilson’s disease: From copper overload to cirrhosis. J Inorg Biochem 2019; 193: 106-11.
[http://dx.doi.org/10.1016/j.jinorgbio.2019.01.008] [PMID: 30703747]
[25]
Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson’s disease. Lancet 2007; 369(9559): 397-408.
[http://dx.doi.org/10.1016/S0140-6736(07)60196-2] [PMID: 17276780]
[26]
Gupta S. Cell therapy to remove excess copper in Wilson’s disease. Ann N Y Acad Sci 2014; 1315: 70-80.
[http://dx.doi.org/10.1111/nyas.12450] [PMID: 24820353]
[27]
Ranucci G, Polishchuck R, Iorio R. Wilson’s disease: prospective developments towards new therapies. World J Gastroenterol 2017; 23(30): 5451-6.
[http://dx.doi.org/10.3748/wjg.v23.i30.5451] [PMID: 28852304]
[28]
Kim BE, Nevitt T, Thiele DJ. Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 2008; 4(3): 176-85.
[http://dx.doi.org/10.1038/nchembio.72] [PMID: 18277979]
[29]
Follenzi A, Benten D, Novikoff P, Faulkner L, Raut S, Gupta S. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest 2008; 118(3): 935-45.
[http://dx.doi.org/10.1172/JCI32748] [PMID: 18274668]
[30]
Joseph B, Kumaran V, Berishvili E, Bhargava KK, Palestro CJ, Gupta S. Monocrotaline promotes transplanted cell engraftment and advances liver repopulation in rats via liver conditioning. Hepatology 2006; 44(6): 1411-20.
[http://dx.doi.org/10.1002/hep.21416] [PMID: 17133480]
[31]
Kobolak J, Dinnyes A, Memic A, Khademhosseini A, Mobasheri A. Mesenchymal stem cells: Identification, phenotypic characterization, biological properties and potential for regenerative medicine through biomaterial micro-engineering of their niche. Methods 2016; 99: 62-8.
[http://dx.doi.org/10.1016/j.ymeth.2015.09.016] [PMID: 26384580]
[32]
Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther 2006; 1(3): 365-9.
[http://dx.doi.org/10.2174/157488806778226821] [PMID: 18220880]
[33]
Mushahary D, Spittler A, Kasper C, Weber V, Charwat V. Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A 2018; 93(1): 19-31.
[http://dx.doi.org/10.1002/cyto.a.23242] [PMID: 29072818]
[34]
Cao Y, Ji C, Lu L. Mesenchymal stem cell therapy for liver fibrosis/cirrhosis. Ann Transl Med 2020; 8(8): 562.
[http://dx.doi.org/10.21037/atm.2020.02.119] [PMID: 32775363]
[35]
Tsuchiya A, Takeuchi S, Watanabe T, et al. Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regeneration. Inflamm Regen 2019; 39: 18.
[http://dx.doi.org/10.1186/s41232-019-0107-z] [PMID: 31516638]
[36]
Yagi K, Kojima M, Oyagi S, et al. [Application of mesenchymal stem cells to liver regenerative medicine]. Yakugaku Zasshi 2008; 128(1): 3-9.
[http://dx.doi.org/10.1248/yakushi.128.3] [PMID: 18176050]
[37]
Kharaziha P, Hellström PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21(10): 1199-205.
[http://dx.doi.org/10.1097/MEG.0b013e32832a1f6c] [PMID: 19455046]
[38]
Suk KT, Yoon JH, Kim MY, et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology 2016; 64(6): 2185-97.
[http://dx.doi.org/10.1002/hep.28693] [PMID: 27339398]
[39]
Sato Y, Araki H, Kato J, et al. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 2005; 106(2): 756-63.
[http://dx.doi.org/10.1182/blood-2005-02-0572] [PMID: 15817682]
[40]
Aurich I, Mueller LP, Aurich H, et al. Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. Gut 2007; 56(3): 405-15.
[http://dx.doi.org/10.1136/gut.2005.090050] [PMID: 16928726]
[41]
Allen KJ, Cheah DM, Lee XL, et al. The potential of bone marrow stem cells to correct liver dysfunction in a mouse model of Wilson’s disease. Cell Transplant 2004; 13(7-8): 765-73.
[http://dx.doi.org/10.3727/000000004783983341] [PMID: 15690978]
[42]
Sauer V, Siaj R, Todorov T, Zibert A, Schmidt HH. Overexpressed ATP7B protects mesenchymal stem cells from toxic copper. Biochem Biophys Res Commun 2010; 395(3): 307-11.
[http://dx.doi.org/10.1016/j.bbrc.2010.03.158] [PMID: 20362556]
[43]
Zhang D. A clinical study of bone mesenchymal stem cells for the treatment of hepatic fibrosis induced by hepatolenticular degeneration. Genet Mol Res 2017; 16(1): 16.
[http://dx.doi.org/10.4238/gmr16019352] [PMID: 28301671]
[44]
Fujiyoshi J, Yamaza H, Sonoda S, et al. Therapeutic potential of hepatocyte-like-cells converted from stem cells from human exfoliated deciduous teeth in fulminant Wilson’s disease. Sci Rep 2019; 9(1): 1535.
[http://dx.doi.org/10.1038/s41598-018-38275-y] [PMID: 30733544]
[45]
Mudrabettu C, Kumar V, Rakha A, et al. Safety and efficacy of autologous mesenchymal stromal cells transplantation in patients undergoing living donor kidney transplantation: a pilot study. Nephrology (Carlton) 2015; 20(1): 25-33.
[http://dx.doi.org/10.1111/nep.12338] [PMID: 25230334]
[46]
Wang X, Montini E, Al-Dhalimy M, Lagasse E, Finegold M, Grompe M. Kinetics of liver repopulation after bone marrow transplantation. Am J Pathol 2002; 161(2): 565-74.
[http://dx.doi.org/10.1016/S0002-9440(10)64212-5] [PMID: 12163381]
[47]
He C, Yang Y, Zheng K, et al. Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges. Ther Adv Chronic Dis 2021; 12: 2040622321993442.
[http://dx.doi.org/10.1177/2040622321993442] [PMID: 33633826]
[48]
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-72.
[http://dx.doi.org/10.1016/j.cell.2007.11.019] [PMID: 18035408]
[49]
Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-20.
[http://dx.doi.org/10.1126/science.1151526] [PMID: 18029452]
[50]
Loh YH, Agarwal S, Park IH, et al. Generation of induced pluripotent stem cells from human blood. Blood 2009; 113(22): 5476-9.
[http://dx.doi.org/10.1182/blood-2009-02-204800] [PMID: 19299331]
[51]
Glicksman MA. Induced Pluripotent Stem Cells: The Most Versatile Source for Stem Cell Therapy. Clin Ther 2018; 40(7): 1060-5.
[http://dx.doi.org/10.1016/j.clinthera.2018.06.004] [PMID: 30049501]
[52]
Huang CY, Liu CL, Ting CY, et al. Human iPSC banking: barriers and opportunities. J Biomed Sci 2019; 26(1): 87.
[http://dx.doi.org/10.1186/s12929-019-0578-x] [PMID: 31660969]
[53]
Deuse T, Hu X, Gravina A, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol 2019; 37(3): 252-8.
[http://dx.doi.org/10.1038/s41587-019-0016-3] [PMID: 30778232]
[54]
Yi F, Qu J, Li M, et al. Establishment of hepatic and neural differentiation platforms of Wilson’s disease specific induced pluripotent stem cells. Protein Cell 2012; 3(11): 855-63.
[http://dx.doi.org/10.1007/s13238-012-2064-z] [PMID: 22806248]
[55]
Liu H, Kim Y, Sharkis S, Marchionni L, Jang YY. In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med 2011; 3(82): 82ra39.
[http://dx.doi.org/10.1126/scitranslmed.3002376] [PMID: 21562231]
[56]
Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013; 499(7459): 481-4.
[http://dx.doi.org/10.1038/nature12271] [PMID: 23823721]
[57]
Asgari S, Moslem M, Bagheri-Lankarani K, Pournasr B, Miryounesi M, Baharvand H. Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells. Stem Cell Rev Rep 2013; 9(4): 493-504.
[http://dx.doi.org/10.1007/s12015-011-9330-y] [PMID: 22076752]
[58]
Tobin SC, Kim K. Generating pluripotent stem cells: differential epigenetic changes during cellular reprogramming. FEBS Lett 2012; 586(18): 2874-81.
[http://dx.doi.org/10.1016/j.febslet.2012.07.024] [PMID: 22819821]
[59]
Cai J, Zhao Y, Liu Y, et al. Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 2007; 45(5): 1229-39.
[http://dx.doi.org/10.1002/hep.21582] [PMID: 17464996]
[60]
Duan Y, Catana A, Meng Y, et al. Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells in vitro and in vivo. Stem Cells 2007; 25(12): 3058-68.
[http://dx.doi.org/10.1634/stemcells.2007-0291] [PMID: 17885076]
[61]
Tolosa L, Caron J, Hannoun Z, et al. Transplantation of hESC-derived hepatocytes protects mice from liver injury. Stem Cell Res Ther 2015; 6: 246.
[http://dx.doi.org/10.1186/s13287-015-0227-6] [PMID: 26652177]
[62]
Touboul T, Hannan NR, Corbineau S, et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 2010; 51(5): 1754-65.
[http://dx.doi.org/10.1002/hep.23506] [PMID: 20301097]
[63]
Siller R, Greenhough S, Naumovska E, Sullivan GJ. Small- molecule-driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Reports 2015; 4(5): 939-52.
[http://dx.doi.org/10.1016/j.stemcr.2015.04.001] [PMID: 25937370]
[64]
Choi D, Oh HJ, Chang UJ, et al. In vivo differentiation of mouse embryonic stem cells into hepatocytes. Cell Transplant 2002; 11(4): 359-68.
[http://dx.doi.org/10.3727/000000002783985792] [PMID: 12162376]
[65]
Moriya K, Yoshikawa M, Saito K, et al. Embryonic stem cells develop into hepatocytes after intrasplenic transplantation in CCl4-treated mice. World J Gastroenterol 2007; 13(6): 866-73.
[http://dx.doi.org/10.3748/wjg.v13.i6.866] [PMID: 17352015]
[66]
Peng F, Lutsenko S, Sun X, Muzik O. Positron emission tomography of copper metabolism in the Atp7b-/- knock-out mouse model of Wilson’s disease. Mol Imaging Biol 2012; 14(1): 70-8.
[http://dx.doi.org/10.1007/s11307-011-0476-4] [PMID: 21327972]

Rights & Permissions Print Cite
Article Metrics
92
2
© 2024 Bentham Science Publishers | Privacy Policy